Physician profile
Kevin E Moore
NPI 1104111590
$1,023.48
in general payments reported to CMS, 2019-2025
17 companies · $248 in 2025
The $248 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $265 · 2020: $57.03 · 2022: $127 · 2023: $104 · 2024: $223 · 2025: $248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $574.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $574.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $284.76 | 2022-2025 | Nuzyra |
| Smith+Nephew, INC. | $213.81 | 2019-2024 | Collagenase Santyl, Regranex |
| Organogenesis INC. | $80.05 | 2020-2025 | Puraply Wound Matrix |
| Depuy Synthes Sales INC. | $78.69 | 2022-2023 | Na, Motoband |
| Kerecis Limited | $71.57 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Horizon Therapeutics Plc | $43.98 | 2019-2023 | Krystexxa |
| Solventum Corporation | $36.63 | 2024-2025 | Activ.A.C., V.A.C. Granufoam, 3m Cavilon |
| Osteomed LLC | $33.62 | 2019-2020 | |
| Integra Lifesciences Corporation | $26.98 | 2019 | |
| Biowound Solutions, INC. | $26.92 | 2025 | Bio-Connekt |
| Stryker Corporation | $24.24 | 2024 | Ortholoc 3di, Tenfuse, 7 X 23mm Citrelock Implant |
| Treace Medical Concepts, INC. | $21.55 | 2023 | |
| Osiris Therapeutics INC. | $19.46 | 2019 | |
| Medline Industries LP | $19.18 | 2019 | |
| Kci USA, INC. | $14.53 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paragon 28, INC. | $13.91 | 2019 | |
| Merck Sharp & Dohme LLC | $13.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.